BB will have access to 100 million doses of vaccines annually and commercialization rights of the SILS vaccine portfolio for global markets
Domestic market and developing countries will need doses of Indian vaccines
A new market study published by Global Industry Analysts (GIA), released its report titled, ``Healthcare Supply Chain Management—Global Market Trajectory & Analytics.’’ We present excerpts from the report
The healthcare vertical is US-focused, has 35-plus clients and 24,000 employees across 34 locations in five countries
The Indian pharma industry has grown at a compounded growth rate of ~11% in the domestic market and ~16% in exports over the last two decades
With cost optimization leading to cumulative savings of US $80 million over last 8 years, the company now aims to tap bigger opportunities in generics business
The rating on senior secured notes issued by Biocon Biologics Global PLC was also upgraded to ‘BB+.’
The Phase III programme, Enith1 and Enith2, is expected to launch this quarter
The upcoming Phase I trial will test the safety, tolerability, and pharmacokinetics of ISM8969 in healthy volunteers and determine the optimal dosing for future studies
The platform uses cutting-edge AI and automation to tackle the entire revenue cycle
Subscribe To Our Newsletter & Stay Updated
